Keep An Eye On Regeneron
December 12, 2016 at 14:17 PM EST
Ophthotech ’s ( OPHT ) loss is a big gain for Regeneron ( REGN ). The drug maker’s stock spiked 5% to $391.27 today after a rival’s experimental treatment for age-related macular degeneration, an eye disease that causes blindness in the elder, failed in late-stage clinical trials.